Correction to: GMMA Technology for the Development of Safe Vaccines: Meta-Analysis of Individual Patient Data to Assess the Safety Profile of Shigella sonnei 1790GAHB Vaccine in Healthy Adults, with Special Focus on Neutropenia
Infect Dis Ther
.
2022 Jun;11(3):1313.
doi: 10.1007/s40121-022-00634-8.
Authors
Iris De Ryck
1
,
Eleanna Sarakinou
2
,
Usman Nakakana
2
,
Giulia Luna Cilio
3
,
Augustin Ndiaye
4
,
Venanzio Vella
3
,
Joachim Auerbach
2
5
,
Juan-Paolo Granada
6
,
Valentino Conti
2
,
Audino Podda
2
Affiliations
1
GSK, Siena, Italy. iris.x.de-ryck@gsk.com.
2
GSK Vaccines Institute for Global Health, Via Fiorentina 1, 53100, Siena, Italy.
3
GSK, Siena, Italy.
4
Takeda Pharmaceutical International AG, Zurich, Switzerland.
5
Coalition for Epidemic Preparedness Innovations, London, UK.
6
Ferring Pharmaceuticals, Copenhagen, Denmark.
PMID:
35435576
PMCID:
PMC9124245
DOI:
10.1007/s40121-022-00634-8
No abstract available
Publication types
Published Erratum